Advances in Pharmaceutical Research and Development through Artificial Intelligence and Machine Learning: A Review

Abstract

Artificial intelligence (AI) and machine learning (ML) are emerging as transformative tools in the pharmaceutical industry, particularly in drug discovery and development. By enabling rapid analysis of vast datasets, AI can accelerate virtual screening, molecular design, target identification, and prediction of drug efficacy and toxicity, ultimately reducing the cost and time associated with traditional research and development. Despite these advances, the successful application of AI depends on access to high-quality, unbiased datasets, robust model validation, and the resolution of ethical challenges such as data privacy, regulatory acceptance, and algorithmic transparency. The current limitations of AI-based approaches, including data scarcity, endpoint heterogeneity, and the “black box” nature of many deep learning models, restrict their full integration into clinical and regulatory workflows. This review explores the benefits, challenges, and drawbacks of AI in the pharmaceutical sector, emphasizing both its potential and its constraints. Strategies to overcome existing barriers are discussed, including data augmentation to address limited training datasets, the adoption of explainable AI frameworks to improve interpretability, and the integration of computational models with traditional experimental methods for enhanced reliability. The convergence of AI with precision medicine and real-world data also holds promise for improving personalized therapeutic strategies. Overall, AI has the potential to revolutionize drug discovery, provided that its limitations are recognized and addressed. Interdisciplinary collaboration between AI researchers, pharmaceutical scientists, and regulatory bodies will be essential to ensure its responsible, ethical, and effective implementation in future therapeutics.

Ähnliche Arbeiten